HDAC9 and familial pancreatic carcinoma: In addition, CG-745, a new clinical stage histone deacetylase (HDAC) inhibitor produced by CrystalGenomics (a biopharmaceutical company from Korea), has recently been granted as Orphan Drug Designation by FDA for pancreatic cancer (http://www.crystalgenomics.com/), which is currently in Phase II pancreatic cancer trial and the results look promising thus far.